1. Home
  2. IMRX

as of 12-31-2025 3:39pm EST

$6.54
$0.19
-2.82%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Founded: 2008 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 366.1M IPO Year: 2021
Target Price: $17.20 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.76 EPS Growth: N/A
52 Week Low/High: $1.10 - $10.08 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered IMRX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 76.00%
76.00%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Immuneering Corporation (IMRX)

Buy
IMRX Oct 3, 2025

Avg Cost/Share

$6.67

Shares

7,500

Total Value

$50,025.00

Owned After

156,766

SEC Form 4

Latest Immuneering Corporation News

IMRX Breaking Stock News: Dive into IMRX Ticker-Specific Updates for Smart Investing

All IMRX News

Share on Social Networks: